Loading
Letetresgene autoleucel is a second engineered T-cell receptor therapy for sarcoma, targeting NY-ESO-1 in synovial sarcoma and myxoid/round cell liposarcoma; a BLA is expected by the end of 2026.
Letetresgene autoleucel is an engineered T-cell receptor therapy: the patient's own T cells receive an affinity-enhanced TCR that recognises the NY-ESO-1/LAGE-1a peptide presented on HLA-A*02, then are returned after lymphodepletion. Its targets are synovial sarcoma and myxoid/round cell liposarcoma (MRCLS), two rare sarcomas that usually express NY-ESO-1. In the pivotal phase 2 IGNYTE-ESO trial, the ORR by independent review was 42% (27 of 64), with 41% in synovial sarcoma and 43% in MRCLS, and a median duration of response of 12.2 months overall and 18.3 months in synovial sarcoma. It holds Breakthrough Therapy designation for MRCLS. Rights passed from GSK to Adaptimmune in 2023 and to US WorldMeds in August 2025, which committed to a BLA by 31 December 2026. It is a one-time infusion of T cells re-engineered to see an antigen these two sarcomas display.
Autologous T cells with an affinity-enhanced TCR against NY-ESO-1/LAGE-1a peptide on HLA-A*02; lymphodepletion then infusion. Connects to HLA-A.
1.Letetresgene autoleucel slips into a pocket on HLA-A.
Breakthrough Therapy for MRCLS
Asset transferred to US WorldMeds; BLA committed by end-2026
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Letetresgene autoleucel" OR ABSTRACT:"Letetresgene autoleucel" OR TITLE:"lete-cel" OR ABSTRACT:"lete-cel" OR TITLE:"GSK3377794" OR ABSTRACT:"GSK3377794") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Letetresgene autoleucel, not a curated reading list.
Shares Extending sarcoma TCR-T beyond HLA-A*02, US WorldMeds, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, HLA-A.
Shares IGNYTE-ESO, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Extending sarcoma TCR-T beyond HLA-A*02, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, HLA-A, TCR-T cell therapy.
Shares CTAG1B, Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
Shares SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).